125 related articles for article (PubMed ID: 16167515)
21. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
22. Bacterial and fungal meningitis and antimicrobial susceptibility pattern in Tikur Anbessa University Hospital, Addis Ababa, Ethiopia.
Mengistu M; Asrat D; Woldeamanuel Y; Mengistu G
Ethiop Med J; 2011 Oct; 49(4):349-59. PubMed ID: 23409400
[TBL] [Abstract][Full Text] [Related]
23. [Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Sfax-Tunisia (1993-1998)].
Ben Jemaa Z; Mahjoubi F; Ben Haj H'mida Y; Hammami N; Ben Ayed M; Hammami A
Pathol Biol (Paris); 2004 Mar; 52(2):82-8. PubMed ID: 15001236
[TBL] [Abstract][Full Text] [Related]
24. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
25. An overview of antimicrobial susceptibility patterns for gram-negative bacteria from the National Antimicrobial Resistance Surveillance Thailand (NARST) program from 2000 to 2005.
Apisarnthanarak A; Buppunharun W; Tiengrim S; Sawanpanyalert P; Aswapokee N
J Med Assoc Thai; 2009 Aug; 92 Suppl 4():S91-4. PubMed ID: 21298849
[TBL] [Abstract][Full Text] [Related]
26. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
Jones RN; Kirby JT; Rhomberg PR
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
[TBL] [Abstract][Full Text] [Related]
28. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ
Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
[TBL] [Abstract][Full Text] [Related]
29. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities.
Wisplinghoff H; Seifert H; Tallent SM; Bischoff T; Wenzel RP; Edmond MB
Pediatr Infect Dis J; 2003 Aug; 22(8):686-91. PubMed ID: 12913767
[TBL] [Abstract][Full Text] [Related]
30. Bacterial profile and patterns of antimicrobial drug resistance in intra-abdominal infections: current experience in a teaching hospital.
Shree N; Arora BS; Mohil RS; Kasana D; Biswal I
Indian J Pathol Microbiol; 2013; 56(4):388-92. PubMed ID: 24441227
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
Kanj SS; Whitelaw A; Dowzicky MJ
Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial susceptibility of common bacterial pathogens isolated from a new regional hospital in southern Taiwan.
Chen HM; Chung PW; Yu YJ; Tai WL; Kao WL; Chien YL; Chiu CH
Chang Gung Med J; 2003 Dec; 26(12):889-96. PubMed ID: 15008323
[TBL] [Abstract][Full Text] [Related]
33. Fifteen years of surveillance by the Australian Group for Antimicrobial Resistance (AGAR).
Nimmo GR; Bell JM; Collignon PJ;
Commun Dis Intell Q Rep; 2003; 27 Suppl():S47-54. PubMed ID: 12807274
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints.
Papaparaskevas J; Tzouvelekis LS; Tsakris A; Pittaras TE; Legakis NJ;
Diagn Microbiol Infect Dis; 2010 Feb; 66(2):187-94. PubMed ID: 19836184
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
36. Monitoring of antibiotic resistance in bacterial isolates from bacteremic patients.
Blahová J; Králiková K; Krcméry V; Babálová M; Menkyna R; Glosová L; Knotková H; Lisková A; Molokácová M; Vaculíková A
J Chemother; 2004 Jun; 16(3):269-72. PubMed ID: 15330324
[TBL] [Abstract][Full Text] [Related]
37. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
38. Changing trends in antimicrobial resistance of major bacterial pathogens, 1985-2005: a study from a medical center in northern Taiwan.
Lo WT; Lin WJ; Chiueh TS; Lee SY; Wang CC; Lu JJ
J Microbiol Immunol Infect; 2011 Apr; 44(2):131-8. PubMed ID: 21439516
[TBL] [Abstract][Full Text] [Related]
39. [In vitro activity of trovafloxacin, of other fluoroquinolones and of related antimicrobials against clinical isolates. Grupo colaborativo WHONET-Argentina].
Rossi A; Galas M; Tokumoto M; Guelfand L; Lopardo H
Medicina (B Aires); 1999; 59 Suppl 1():8-16. PubMed ID: 10436549
[TBL] [Abstract][Full Text] [Related]
40. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
